LYEL

LYELL IMMUNOPHARMA INC

LYEL·55083R203·US·Common Stock·Healthcare - Biotechnology-13D/G

LYEL (LYELL IMMUNOPHARMA INC) is held by 47 institutional investors as of Q1 2026. Largest holders: VANGUARD CAPITAL MANAGEMENT LLC ($14.4M), MILLENNIUM MANAGEMENT LLC ($9.2M), CITADEL ADVISORS LLC ($7.7M). Net institutional sentiment: Bullish.

47
Holders
Avg rating(6 Elite)
$73.3M
Total Value
76% (51)
Fund Consensus
32 buying - 10 selling
LYELSmart Money Verdict
View all
Held by 47 funds
6 elite
Who's Trading
ActivistICInnovative Cellular Therapeutics Holdings Limited12.3%Jun 18, 2026
InsiderSDShook DavidSell $25KJun 10, 2026
ActivistAVARCH Venture Fund IX, L.P.13.9%May 15, 2026
InsiderHJHill Stephen J.Sell $2KMay 11, 2026
InsiderLKLee Gary K.Sell $2KMay 11, 2026
InsiderBSBulis Veronica SanchezSell $4KMay 11, 2026
ActivistMCMWG Caph Ltd4.3%May 11, 2026
ActivistEIExplore Investments LLC6.6%May 8, 2026
ActivistEUEULER FUND, L.P.6.7%Apr 21, 2026
InsiderALARCH Venture Fund XIII, L.P.Buy $12.5MMar 6, 2026
13F: Insider & Congress:
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
New
718,155$14.4M0.0%-35.66%
39
Increased
458,905(+682.4%)$9.2M0.0%-34.93%
45
Increased
381,462(+17.5%)$7.7M0.0%+4.93%
32
Increased
310,198(+105.4%)$6.2M0.0%-43.33%
44
Unchanged
293,256$5.9M0.1%-78.37%
0
Increased
191,820(+5.5%)$3.8M0.0%+7.87%
28
Increased
166,980(+2.4%)$3.4M0.0%-82.01%
27
Increased
148,516(+102.6%)$3M0.0%-45.23%
43
Increased
116,411(+194.8%)$2.3M0.0%-27.30%
42
Increased
114,491(+18.4%)$2.3M0.0%-50.47%
31
New
86,925$1.7M0.0%-35.66%
36
Increased
85,971(+0.6%)$1.7M0.0%-80.94%
26
Increased
72,522(+40.9%)$1.5M0.0%-53.79%
34
Increased
63,893(+414.9%)$1.3M0.0%-39.80%
41
Increased
56,151(+30.7%)$1.1M0.0%-41.18%
32
Increased
55,110(+508.9%)$1.1M0.0%-39.20%
41
New
47,888$958,9990.0%-35.66%
35
Increased
33,321(+314.2%)$668,4200.0%-33.68%
27
Increased
31,814(+141.0%)$638,1880.0%-28.50%
39
Unchanged
30,280$607,4170.0%-83.48%
0

Showing 1-20 of 51

1 / 3

Other Healthcare stocks held by institutions

Data sourced from four SEC data sources: 13F, Form 4, 13D/13G, and STOCK Act. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used